Association between response to triptans and response to erenumab: real-life data [PDF]
The Journal of Headache and Pain, 2021 Background Triptans and erenumab are both migraine-specific agents acting on the calcitonin gene-related peptide pathway. Therefore, response to triptans might be associated with response to erenumab.
Ilaria Frattale +14 more
doaj +3 more sources
Tolerability of switch from erenumab to fremanezumab in adults with chronic migraine: a 3-month, single-center, prospective, real-world, observational study [PDF]
The Journal of Headache and PainObjective While erenumab and fremanezumab are effective treatments for migraine prevention, it is unclear whether patients who experience adverse events related to erenumab can tolerate fremanezumab.
Faisal Mohammad Amin +4 more
doaj +2 more sources
Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results [PDF]
The Journal of Headache and Pain, 2022 Background The fully human monoclonal antibody erenumab, which targets the calcitonin gene-related peptide (CGRP) receptor, was licensed in Switzerland in July 2018 for the prophylactic treatment of migraine.
Andreas R. Gantenbein +14 more
doaj +2 more sources
Sequential use of OnabotulinumtoxinA and Erenumab in Chronic Migraine: Retrospective Real-World Report on Bidirectional Switching [PDF]
Neurology and TherapyIntroduction In clinical practice, switching between preventive treatments is common in patients with chronic migraine when efficacy is insufficient or tolerability is poor.
Carolin Luisa Hoehne +7 more
doaj +2 more sources
The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal [PDF]
The Journal of Headache and Pain, 2019 Background Erenumab, a fully human monoclonal antibody directed against the calcitonin gene-related peptide receptor, was approved for the prevention of episodic (EM) or chronic migraine (CM) at the monthly dose of 70 mg or 140 mg.
Raffaele Ornello +6 more
doaj +3 more sources
Swiss Quality of Life and Health Care Impact Assessment in a Real-World Erenumab-Treated Migraine Population: Results over 2 years. [PDF]
HeadacheThis prospective, multicenter, noninterventional cohort study evaluated the impact of erenumab on the quality of life and migraine-related impairment of adult patients with migraine, as well as the drug's tolerability in a real-world setting over 2 years.
Gantenbein AR +11 more
europepmc +3 more sources
Unveiling the efficacy and safety of Erenumab, a monoclonal antibody targeting calcitonin gene-related peptide (CGRP) receptor, in patients with chronic and episodic migraine: a GRADE-assessed systematic review and meta-analysis of randomized clinical trials with subgroup analysis [PDF]
Head & Face MedicineBackground Migraine is a highly prevalent and disabling disease, affecting nearly 14% of the global population. Preventive medications involve drugs like beta-adrenergic blockers, antidepressants, and anticonvulsants.
Mohamed E. Haseeb +6 more
doaj +2 more sources
Brain Sciences, 2021 Background: We aimed to assess the differences between menstrual and non-menstrual headache in women with chronic migraine treated with erenumab. Methods: We included fertile women from a single center.
Raffaele Ornello +5 more
doaj +1 more source
Hospital Pharmacy, 2018 Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
Kalvin, Stoker, Danial E, Baker
openaire +2 more sources
Erenumab effectiveness and safety: comparison of real-life data and clinical trial results
Neurologijos seminarai, 2021 Background. Erenumab was the first preventive medication targeted to the pathogenesis of migraine to reach Lithuanian market. Previously, evidence of the safety and efficacy of erenumab was supported only by clinical study results, but more recently ...
Austėja Dapkutė , K. Ryliškienė
doaj +1 more source